Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback
~ Productive FDA Meeting Highlights Path Toward Overdose Protection Labeling and 505(b)(2) Regulatory Strategy ~ ~ FDA and Ensysce Aligned on Collaborative Approach to Ensure Product’s Full Safety Benefits are Recognized ~ SAN DIEGO, CA / ACCESS Newswire / July 31, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical innovator […]